Biopharmx Corp (NYSE:BPMX) was the recipient of a significant decline in short interest in July. As of July 31st, there was short interest totalling 4,790,336 shares, a decline of 6.7% from the July 14th total of 5,135,164 shares. Approximately 8.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 697,859 shares, the days-to-cover ratio is presently 6.9 days.
Separately, ValuEngine upgraded Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 24th.
Shares of Biopharmx Corp (NYSE BPMX) opened at 0.298 on Thursday. The stock’s market capitalization is $22.09 million. Biopharmx Corp has a 1-year low of $0.19 and a 1-year high of $1.22. The company has a 50 day moving average price of $0.44 and a 200-day moving average price of $0.52.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.